These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 9336320)

  • 1. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461.
    Van Heek M; France CF; Compton DS; McLeod RL; Yumibe NP; Alton KB; Sybertz EJ; Davis HR
    J Pharmacol Exp Ther; 1997 Oct; 283(1):157-63. PubMed ID: 9336320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663.
    van Heek M; Farley C; Compton DS; Hoos L; Alton KB; Sybertz EJ; Davis HR
    Br J Pharmacol; 2000 Apr; 129(8):1748-54. PubMed ID: 10780982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HPLC-NMR with severe column overloading: fast-track metabolite identification in urine and bile samples from rat and dog treated with [14C]-ZD6126.
    Lenz EM; D'Souza RA; Jordan AC; King CD; Smith SM; Phillips PJ; McCormick AD; Roberts DW
    J Pharm Biomed Anal; 2007 Feb; 43(3):1065-77. PubMed ID: 17030109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys.
    Tan EY; Hartmann G; Chen Q; Pereira A; Bradley S; Doss G; Zhang AS; Ho JZ; Braun MP; Dean DC; Tang W; Kumar S
    Drug Metab Dispos; 2010 Mar; 38(3):459-73. PubMed ID: 20016052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.
    Rosenblum SB; Huynh T; Afonso A; Davis HR; Yumibe N; Clader JW; Burnett DA
    J Med Chem; 1998 Mar; 41(6):973-80. PubMed ID: 9526571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats.
    van Heek M; Farley C; Compton DS; Hoos LM; Smith-Torhan A; Davis HR
    Br J Pharmacol; 2003 Apr; 138(8):1459-64. PubMed ID: 12721101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
    Zhang D; Wang L; Raghavan N; Zhang H; Li W; Cheng PT; Yao M; Zhang L; Zhu M; Bonacorsi S; Yeola S; Mitroka J; Hariharan N; Hosagrahara V; Chandrasena G; Shyu WC; Humphreys WG
    Drug Metab Dispos; 2007 Jan; 35(1):150-67. PubMed ID: 17062777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS.
    Prakash C; Soliman V
    Drug Metab Dispos; 1997 Nov; 25(11):1288-97. PubMed ID: 9351906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatotoxic effects of estradiol-17 beta-D-glucuronide in the rat and monkey.
    Slikker W; Vore M; Bailey JR; Meyers M; Montgomery C
    J Pharmacol Exp Ther; 1983 Apr; 225(1):138-43. PubMed ID: 6300372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function.
    van Heek M; Farley C; Compton DS; Hoos L; Davis HR
    Br J Pharmacol; 2001 Sep; 134(2):409-17. PubMed ID: 11564660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of C3 heteroatom-substituted azetidinones that display potent cholesterol absorption inhibitory activity.
    McKittrick BA; Ma K; Huie K; Yumibe N; Davis H; Clader JW; Czarniecki M; McPhail AT
    J Med Chem; 1998 Feb; 41(5):752-9. PubMed ID: 9513603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucuronidation converting methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate (S-8921) to a potent apical sodium-dependent bile acid transporter inhibitor, resulting in a hypocholesterolemic action.
    Sakamoto S; Kusuhara H; Miyata K; Shimaoka H; Kanazu T; Matsuo Y; Nomura K; Okamura N; Hara S; Horie K; Baba T; Sugiyama Y
    J Pharmacol Exp Ther; 2007 Aug; 322(2):610-8. PubMed ID: 17470645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucuronidation as a transient intermediate metabolic step in the elimination of (-)-carbovir. Identification of (-)-carbovir-5'-O-glucuronide in rat bile.
    Zimmerman CL; Iyer KR; Faudskar AL; Remmel RP
    Drug Metab Dispos; 1993; 21(5):902-10. PubMed ID: 7902254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism and biliary excretion of 2,4,5,2',4',5'-hexachlorobiphenyl in the rhesus monkey (Macaca mulatta).
    Norback DH; Mack E; Reddy G; Britt J; Hsia MT
    Res Commun Chem Pathol Pharmacol; 1981 Apr; 32(1):71-85. PubMed ID: 6794118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
    Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
    Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.
    Halpin RA; Geer LA; Zhang KE; Marks TM; Dean DC; Jones AN; Melillo D; Doss G; Vyas KP
    Drug Metab Dispos; 2000 Oct; 28(10):1244-54. PubMed ID: 10997947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism and excretion of atorvastatin in rats and dogs.
    Black AE; Hayes RN; Roth BD; Woo P; Woolf TF
    Drug Metab Dispos; 1999 Aug; 27(8):916-23. PubMed ID: 10421619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orally active inhibitors of human leukocyte elastase. III. Identification and characterization of metabolites of L-694,458 by liquid chromatography-tandem mass spectrometry.
    Luffer-Atlas D; Vincent SH; Painter SK; Arison BH; Stearns RA; Chiu SH
    Drug Metab Dispos; 1997 Aug; 25(8):940-52. PubMed ID: 9280402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism, distribution, and excretion of a next generation selective estrogen receptor modulator, lasofoxifene, in rats and monkeys.
    Prakash C; Johnson KA; Schroeder CM; Potchoiba MJ
    Drug Metab Dispos; 2008 Sep; 36(9):1753-69. PubMed ID: 18515329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid chromatography/nuclear magnetic resonance spectroscopy and liquid chromatography/mass spectrometry identification of novel metabolites of the multidrug resistance modulator LY335979 in rat bile and human liver microsomal incubations.
    Ehlhardt WJ; Woodland JM; Baughman TM; Vandenbranden M; Wrighton SA; Kroin JS; Norman BH; Maple SR
    Drug Metab Dispos; 1998 Jan; 26(1):42-51. PubMed ID: 9443851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.